Holen Sie sich die Stockscreener-App
10.24
0.39%
0.04
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
ORIC: Lead oncology programs progress to phase III with strong funding and promising early data - TradingView
Oric Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - Sahm
Biotech firm ORIC lines up three investor talks this February - Stock Titan
Oric Pharmaceuticals Approaches Critical Clinical Milestones - AD HOC NEWS
Price-Driven Insight from (ORIC) for Rule-Based Strategy - Stock Traders Daily
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Up 8.4%Here's What Happened - MarketBeat
J.P. Morgan Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating - 富途牛牛
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring 95% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 6.8%Time to Sell? - MarketBeat
Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks - Baystreet.ca
Oric Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume IncreaseWhat's Next? - MarketBeat
How Investors Are Reacting To ORIC Pharmaceuticals (ORIC) Big-Pharma Partnerships And Cancer Resistance Pipeline - Sahm
(ORIC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 74% Potential Upside Sparks Investor Interest - directorstalkinterviews.com
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Oric Pharmaceuticals director Heyman sells shares worth $80,430 By Investing.com - Investing.com Australia
Oric Pharmaceuticals director Heyman sells shares worth $80,430 - Investing.com
ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside - Seeking Alpha
Short Interest in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Grows By 19.6% - MarketBeat
ORIC Pharmaceuticals (ORIC) Is Up 32.5% After J&J Lung Cancer Collaboration and Pipeline UpdateWhat's Changed - Sahm
ORIC Pharmaceuticals Stock Pre-Market (-6.1%) : Form 144 Filings Signal Intent to Sell - Trefis
First Week of March 20th Options Trading For Oric Pharmaceuticals (ORIC) - Nasdaq
Volume Summary: Is ORIC Pharmaceuticals Inc forming higher highs and higher lows2025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Is Roma Green Finance Limited gaining market shareJuly 2025 Trends & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing ORIC Pharmaceuticals (ORIC) Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration - Sahm
Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz - Yahoo Finance
H.C. Wainwright reiterates Buy rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
ORIC Pharmaceuticals provides 2025 operational highlights, upcoming milestones - MSN
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - marketscreener.com
ORIC: Advancing two late-stage oncology drugs with pivotal data and trials expected by 2027 - TradingView
Wedbush Reaffirms Outperform Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Wedbush Reiterates Outperform Rating for ORIC at $20 | ORIC Stoc - GuruFocus
ORIC Pharmaceuticals reports progress on cancer drug candidates By Investing.com - Investing.com Nigeria
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ORIC Pharmaceuticals reports progress on cancer drug candidates - Investing.com
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones - Sahm
Oric Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.8% HigherShould You Buy? - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Biotech Gem with 148% Upside Potential - DirectorsTalk Interviews
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded by Piper Sandler to Strong-Buy Rating - MarketBeat
Why ORIC Pharmaceuticals Inc. stock attracts global investors2025 Price Targets & High Win Rate Trade Alerts - Улправда
Is ORIC Pharmaceuticals Inc. stock a buy before product launchesQuarterly Trade Report & Capital Efficient Trading Techniques - Улправда
Will ORIC Pharmaceuticals Inc. (4TZ) stock gain from green policiesEarnings Miss & Stock Timing and Entry Methods - Улправда
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):